Literature DB >> 8046485

The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?

L M Hamberg1, G J Hunter, N M Alpert, N C Choi, J W Babich, A J Fischman.   

Abstract

UNLABELLED: The dose uptake ratio (DUR) has been used as a quantitative index of glucose metabolism for tumor classification and monitoring response to treatment. In order to provide consistent results, DUR measurements should be made when the concentration of tracer has reached a plateau. The time of this plateau cannot be identified from a single static acquisition.
METHODS: In this study, we investigated the changes in DUR as a function of time in eight patients with stage III lung cancer. All patients underwent a quantitative dynamic 18F-FDG PET study before and after treatment and the data were analyzed with a three-compartment model. Using the fitted model parameters, the DUR was predicted at the plateau and intermediate times.
RESULTS: Tumor concentrations of 18F-FDG did not reach a plateau within the 90 min of imaging in any of the pre-treatment studies and only in one case post-treatment. The average time to reach 95% of the plateau value pre-treatment was 298 +/- 42 min (range: 130-500 min); in post-treatment, it was 154 +/- 31 min (range: 65-240 min). The difference between the plateau DUR and the 60-min value was 46% +/- 6% pre-treatment and 17% +/- 5% post-treatment.
CONCLUSIONS: These data indicate that DUR can vary widely with the time of measurement and that DUR should be interpreted with caution in any individual patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046485

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  105 in total

1.  Is quantitation necessary for oncological PET studies? Against.

Authors:  Michael M Graham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01       Impact factor: 9.236

2.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Daniel Appelbaum; Yonglin Pu
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-05-30       Impact factor: 2.924

3.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

4.  Study of an image-derived SUV and a modified SUV using mouse FDG-PET.

Authors:  Xiujuan Zheng; Chin-Lung Yu; Wei Sha; Caius Radu; Sung-Cheng Huang; Dagan Feng
Journal:  Nucl Med Biol       Date:  2010-12-03       Impact factor: 2.408

5.  Comparison of the diagnostic accuracy of PET/MRI to PET/CT-acquired FDG brain exams for seizure focus detection: a prospective study.

Authors:  Michael J Paldino; Erica Yang; Jeremy Y Jones; Nadia Mahmood; Andrew Sher; Wei Zhang; Shireen Hayatghaibi; Ramkumar Krishnamurthy; Victor Seghers
Journal:  Pediatr Radiol       Date:  2017-05-16

6.  The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.

Authors:  Irene A Burger; Hebert Alberto Vargas; Debra A Goldman; Mithat Gonen; Anita Kumar; Andrew D Zelenetz; Heiko Schöder; Hedvig Hricak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

7.  Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.

Authors:  Nanda C Krak; Jacobus J M van der Hoeven; Otto S Hoekstra; Jos W R Twisk; Elsken van der Wall; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-15       Impact factor: 9.236

8.  Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.

Authors:  Shinsuke Sasada; Norio Masumoto; Eri Suzuki; Satoshi Sueoka; Noriko Goda; Keiko Kajitani; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-16       Impact factor: 9.236

9.  Usefulness of additional delayed regional F-18 Fluorodeoxy-Glucose Positron Emission Tomography in the lymph node staging of Non-Small Cell Lung Cancer patients.

Authors:  Young So; June-Key Chung; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

10.  Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.

Authors:  A Stahl; K Ott; M Schwaiger; W A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.